254 related articles for article (PubMed ID: 22869157)
1. The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis.
Takeuchi Y; Ikeda F; Moritou Y; Hagihara H; Yasunaka T; Kuwaki K; Miyake Y; Ohnishi H; Nakamura S; Shiraha H; Takaki A; Iwasaki Y; Nouso K; Yamamoto K
J Gastroenterol; 2013 Mar; 48(3):405-12. PubMed ID: 22869157
[TBL] [Abstract][Full Text] [Related]
2. [Effects of PNPLA3, TM6SF2 gene polymorphisms and its interactions with smoking and alcohol drinking on hepatitis B virus-associated hepatocellular carcinoma].
Wang LQ; Guo WH; Guo ZW; Qin P; Zhang R; Zhu XM; Liu DW
Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Dec; 39(12):1611-1616. PubMed ID: 30572387
[No Abstract] [Full Text] [Related]
3. Association of PNPLA3 Polymorphism with Hepatocellular Carcinoma Development and Prognosis in Viral and Non-Viral Chronic Liver Diseases.
Khlaiphuengsin A; Kiatbumrung R; Payungporn S; Pinjaroen N; Tangkijvanich P
Asian Pac J Cancer Prev; 2015; 16(18):8377-82. PubMed ID: 26745088
[TBL] [Abstract][Full Text] [Related]
4. Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma.
Raksayot M; Chuaypen N; Khlaiphuengsin A; Pinjaroen N; Treeprasertsuk S; Poovorawan Y; Tanaka Y; Tangkijvanich P
J Gastroenterol; 2019 May; 54(5):427-436. PubMed ID: 30506232
[TBL] [Abstract][Full Text] [Related]
5. Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma in Asian chronic hepatitis C patients: A longitudinal study.
Yen YH; Tsai MC; Wu CK; Chang KC; Hung CH; Chiu KW; Lu SN; Wang JH; Chen CH; Kee KM; Kuo YH; Tseng PL; Lin MT; Huang CM; Lin JT; Hu TH
J Formos Med Assoc; 2018 Sep; 117(9):833-840. PubMed ID: 29089161
[TBL] [Abstract][Full Text] [Related]
6. PNPLA3 rs738409 is not associated with the risk of hepatocellular carcinoma and persistent infection of hepatitis B virus (HBV) in HBV-related subjects: A case-control study and meta-analysis on Asians.
Wang P; Wu C; Li Y; Gong Y; Shen N
Gene; 2020 Jun; 742():144585. PubMed ID: 32173542
[TBL] [Abstract][Full Text] [Related]
7. A Variant in PNPLA3 Associated With Fibrosis Progression but not Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection.
Ali M; Yopp A; Gopal P; Beg MS; Zhu H; Lee W; Singal AG
Clin Gastroenterol Hepatol; 2016 Feb; 14(2):295-300. PubMed ID: 26305067
[TBL] [Abstract][Full Text] [Related]
8. No correlation between PNPLA3 rs738409 genotype and fatty liver and hepatic cirrhosis in Japanese patients with HCV.
Nakamura M; Kanda T; Nakamoto S; Miyamura T; Jiang X; Wu S; Yokosuka O
PLoS One; 2013; 8(12):e81312. PubMed ID: 24349054
[TBL] [Abstract][Full Text] [Related]
9. PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence.
Falleti E; Fabris C; Cmet S; Cussigh A; Bitetto D; Fontanini E; Fornasiere E; Bignulin S; Fumolo E; Bignulin E; Pirisi M; Toniutto P
Liver Int; 2011 Sep; 31(8):1137-43. PubMed ID: 21745286
[TBL] [Abstract][Full Text] [Related]
10. PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis.
Guyot E; Sutton A; Rufat P; Laguillier C; Mansouri A; Moreau R; Ganne-Carrié N; Beaugrand M; Charnaux N; Trinchet JC; Nahon P
J Hepatol; 2013 Feb; 58(2):312-8. PubMed ID: 23069476
[TBL] [Abstract][Full Text] [Related]
11. Association between rs738409 polymorphism in patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene and hepatocellular carcinoma susceptibility: Evidence from case-control studies.
Li JF; Zheng EQ; Xie M
Gene; 2019 Feb; 685():143-148. PubMed ID: 30403964
[TBL] [Abstract][Full Text] [Related]
12. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.
Liu YL; Patman GL; Leathart JB; Piguet AC; Burt AD; Dufour JF; Day CP; Daly AK; Reeves HL; Anstee QM
J Hepatol; 2014 Jul; 61(1):75-81. PubMed ID: 24607626
[TBL] [Abstract][Full Text] [Related]
13. The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus.
Ueyama M; Nishida N; Korenaga M; Korenaga K; Kumagai E; Yanai H; Adachi H; Katsuyama H; Moriyama S; Hamasaki H; Sako A; Sugiyama M; Aoki Y; Imamura M; Murata K; Masaki N; Kawaguchi T; Torimura T; Hyogo H; Aikata H; Ito K; Sumida Y; Kanazawa A; Watada H; Okamoto K; Honda K; Kon K; Kanto T; Mizokami M; Watanabe S
J Gastroenterol; 2016 Apr; 51(4):370-9. PubMed ID: 26337813
[TBL] [Abstract][Full Text] [Related]
14. PNPLA3 I148M polymorphism, clinical presentation, and survival in patients with hepatocellular carcinoma.
Valenti L; Motta BM; Soardo G; Iavarone M; Donati B; Sangiovanni A; Carnelutti A; Dongiovanni P; Rametta R; Bertelli C; Facchetti F; Colombo M; Fargion S; Fracanzani AL
PLoS One; 2013; 8(10):e75982. PubMed ID: 24155878
[TBL] [Abstract][Full Text] [Related]
15. The impact of PNPLA3 (rs738409 C>G) polymorphisms on liver histology and long-term clinical outcome in chronic hepatitis B patients.
Brouwer WP; van der Meer AJ; Boonstra A; Pas SD; de Knegt RJ; de Man RA; Hansen BE; ten Kate FJ; Janssen HL
Liver Int; 2015 Feb; 35(2):438-47. PubMed ID: 25284145
[TBL] [Abstract][Full Text] [Related]
16. Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease.
Grimaudo S; Pipitone RM; Pennisi G; Celsa C; Cammà C; Di Marco V; Barcellona MR; Boemi R; Enea M; Giannetti A; Spatola F; Marchesini G; Craxì A; Petta S
Clin Gastroenterol Hepatol; 2020 Apr; 18(4):935-944.e3. PubMed ID: 31419571
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in MICA, but not in DEPDC5, HCP5 or PNPLA3, are associated with chronic hepatitis C-related hepatocellular carcinoma.
Hai H; Tamori A; Thuy LTT; Yoshida K; Hagihara A; Kawamura E; Uchida-Kobayashi S; Morikawa H; Enomoto M; Murakami Y; Kawada N
Sci Rep; 2017 Sep; 7(1):11912. PubMed ID: 28928439
[TBL] [Abstract][Full Text] [Related]
18. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction.
Hassan MM; Kaseb A; Etzel CJ; El-Serag H; Spitz MR; Chang P; Hale KS; Liu M; Rashid A; Shama M; Abbruzzese JL; Loyer EM; Kaur H; Hassabo HM; Vauthey JN; Wray CJ; Hassan BS; Patt YZ; Hawk E; Soliman KM; Li D
Mol Carcinog; 2013 Nov; 52 Suppl 1(0):E139-47. PubMed ID: 23776098
[TBL] [Abstract][Full Text] [Related]
19. Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination.
Ogawa E; Takayama K; Hiramine S; Hayashi T; Toyoda K
Aliment Pharmacol Ther; 2020 Sep; 52(5):866-876. PubMed ID: 32697871
[TBL] [Abstract][Full Text] [Related]
20. PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases.
Yang J; Trépo E; Nahon P; Cao Q; Moreno C; Letouzé E; Imbeaud S; Gustot T; Deviere J; Debette S; Amouyel P; Bioulac-Sage P; Calderaro J; Ganne-Carrié N; Laurent A; Blanc JF; Guyot E; Sutton A; Ziol M; Zucman-Rossi J; Nault JC
Int J Cancer; 2019 Feb; 144(3):533-544. PubMed ID: 30289982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
